2 results match your criteria: "Centro Médico Teknon Hospital[Affiliation]"
Safety and Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Patellar Tendinopathy (With Gap >3 mm) in Patients: 12-Month Follow-up Results of a Phase 1/2 Clinical Trial.
Orthop J Sports Med
September 2023
Institut de Teràpia Regenerativa Tissular (ITRT), Centro Médico Teknon Hospital, Barcelona, Spain.
Article Synopsis
- Previous research showed that patients treated with bone marrow-derived mesenchymal stem cells (BM-MSCs) had better tendon structure and regeneration compared to those treated with leukocyte-poor platelet-rich plasma (Lp-PRP) at the 6-month mark.
- A follow-up study evaluated 20 patients' outcomes at 12 months after BM-MSC treatment, including those who switched from Lp-PRP to BM-MSCs, to assess any potential benefits of the initial treatment.
- Results indicated that while BM-MSCs continued to improve tendon structure and pain, the prior Lp-PRP treatment did not offer any advantages, confirming the effectiveness of BM-MSCs alone.
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.
Cancers (Basel)
October 2021
GEICAM Spanish Breast Cancer Group, 28703 San Sebastián de los Reyes, Spain.
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab (day 1) plus gemcitabine (days 1 and 8). The primary objective was the objective response rate (ORR).
View Article and Find Full Text PDF